New drug duo takes on tough rectal cancer
NCT ID NCT06933251
First seen Jun 24, 2026 · Last updated Jul 09, 2026 · Updated 3 times
Summary
This phase 2 trial is testing whether adding two drugs—a PCSK9 inhibitor and a PD-1 inhibitor—to standard chemoradiotherapy can help shrink tumors in patients with locally advanced rectal cancer that has a specific genetic profile (pMMR/MSS). The study involves 30 participants and aims to see how well the treatment works and how safe it is. The approach is experimental and still in early stages.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PCSK9 inhibitor and PD-1 inhibitor combined with chemoradiotherapy
- What this could lead to
- If successful, this could offer a new treatment option for patients with a hard-to-treat form of rectal cancer, potentially improving tumor response and organ preservation.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination therapy may cause significant side effects, and it is not yet known if it will improve long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
-
No. 106, Zhongshan 2nd Road, Yuexiu District, Guangzhou
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gut bacteria transplant help immunotherapy wipe out rectal cancer before surgery?
- New combo therapy aims to shrink rectal tumors before Surgery—Could spare some patients the knife
- New combo therapy aims to spare organs in High-Risk rectal cancer
- Blood test may predict rectal cancer treatment success
- New drug combo may help avoid surgery in rectal cancer patients
- New combo therapy aims to skip radiation for rectal cancer patients